• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

雄激素剥夺疗法对前列腺癌患者骨密度的影响:一项系统评价和荟萃分析。

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.

作者信息

Kim Do Kyung, Lee Joo Yong, Kim Kwang Joon, Hong Namki, Kim Jong Won, Hah Yoon Soo, Koo Kyo Chul, Kim Jae Heon, Cho Kang Su

机构信息

Department of Urology, Gangnam Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul 06273, Korea.

Department of Urology, Severance Hospital, Urological Science Institute, Yonsei University College of Medicine, Seoul 03722, Korea.

出版信息

J Clin Med. 2019 Jan 18;8(1):113. doi: 10.3390/jcm8010113.

DOI:10.3390/jcm8010113
PMID:30669289
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6352073/
Abstract

We aimed to evaluate the change in bone mineral density (BMD) in patients with prostate cancer (PCa) receiving androgen deprivation therapy (ADT) compared to those with PCa or other urologic conditions not receiving ADT. Literature searches were conducted throughout October 2018. The eligibility of each study was assessed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines using the Participant, Intervention, Comparator, Outcome, and Study design method. The outcomes analyzed were the mean difference (MD) of percent changes in BMD of lumbar spine, femur neck, and total hip. Five prospective cohort studies with a total of 533 patients were included in the present study. Statistically significant decreases of BMD change relative to the control group were observed in the ADT treatment group in the lumbar spine (MD -3.60, 95% CI -6.72 to -0.47, = 0.02), femoral neck (MD -3.11, 95% CI -4.73 to -1.48, = 0.0002), and total hip (MD -1.59, 95% CI -2.99 to -0.19, = 0.03). There is a significant relationship between ADT and BMD reduction in patients with PCa. Regular BMD testing and the optimal treatment for BMD loss should, therefore, be considered in patients with PCa undergoing ADT.

摘要

我们旨在评估接受雄激素剥夺治疗(ADT)的前列腺癌(PCa)患者与未接受ADT的PCa患者或其他泌尿系统疾病患者相比,骨矿物质密度(BMD)的变化。于2018年10月进行了文献检索。根据系统评价和Meta分析的首选报告项目指南,采用参与者、干预措施、对照、结局和研究设计方法对每项研究的纳入资格进行评估。分析的结局是腰椎、股骨颈和全髋关节BMD百分比变化的平均差值(MD)。本研究纳入了5项前瞻性队列研究,共533例患者。在ADT治疗组中,观察到腰椎(MD -3.60,95%CI -6.72至-0.47,P = 0.02)、股骨颈(MD -3.11,95%CI -4.73至-1.48,P = 0.0002)和全髋关节(MD -1.59,95%CI -2.99至-0.19,P = 0.03)的BMD变化相对于对照组有统计学意义的降低。ADT与PCa患者的BMD降低之间存在显著关联。因此,对于接受ADT的PCa患者,应考虑定期进行BMD检测以及对BMD丢失进行最佳治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3555/6352073/014c9bc8b7eb/jcm-08-00113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3555/6352073/7f032733903a/jcm-08-00113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3555/6352073/014c9bc8b7eb/jcm-08-00113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3555/6352073/7f032733903a/jcm-08-00113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3555/6352073/014c9bc8b7eb/jcm-08-00113-g002.jpg

相似文献

1
Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.雄激素剥夺疗法对前列腺癌患者骨密度的影响:一项系统评价和荟萃分析。
J Clin Med. 2019 Jan 18;8(1):113. doi: 10.3390/jcm8010113.
2
Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.男性雄激素剥夺治疗前列腺癌时预防骨质疏松症:系统评价和荟萃分析。
Eur Urol Oncol. 2019 Sep;2(5):551-561. doi: 10.1016/j.euo.2018.11.001. Epub 2018 Nov 24.
3
Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.雄激素剥夺疗法对新西兰前列腺癌队列骨密度的影响:一项试点研究。
Clin Med Insights Oncol. 2017 Oct 9;11:1179554917733449. doi: 10.1177/1179554917733449. eCollection 2017.
4
Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.休闲足球对接受雄激素剥夺治疗的前列腺癌男性患者骨骼健康、身体成分和身体机能的影响:FC前列腺随机对照试验的32周随访
Osteoporos Int. 2016 Apr;27(4):1507-1518. doi: 10.1007/s00198-015-3399-0. Epub 2015 Nov 16.
5
Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.双磷酸盐对接受雄激素剥夺疗法治疗前列腺癌的男性的骨密度的影响。
Clin Genitourin Cancer. 2018 Dec;16(6):e1243-e1250. doi: 10.1016/j.clgc.2018.07.016. Epub 2018 Jul 21.
6
Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy.雄激素剥夺治疗的前列腺癌男性的骨密度、结构、分布和强度。
Bone. 2019 Oct;127:367-375. doi: 10.1016/j.bone.2019.06.005. Epub 2019 Jun 9.
7
Age, body mass index, and serum prostate-specific antigen correlate with bone loss in men with prostate cancer not receiving androgen deprivation therapy.年龄、体重指数和血清前列腺特异性抗原与未接受雄激素剥夺治疗的前列腺癌男性的骨质流失相关。
Urology. 2004 Aug;64(2):335-40. doi: 10.1016/j.urology.2004.03.036.
8
Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.接受或不接受地诺单抗的雄激素剥夺治疗的前列腺癌患者的骨转换/质量标志物及骨密度评估
Anticancer Res. 2017 Jul;37(7):3667-3671. doi: 10.21873/anticanres.11737.
9
Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.前列腺癌患者在接受10年雄激素剥夺治疗后骨密度逐渐下降。
Urology. 2001 Jan;57(1):127-32. doi: 10.1016/s0090-4295(00)00895-5.
10
Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.接受雄激素剥夺治疗的前列腺癌患者的骨矿物质密度、病理性骨折和双膦酸盐治疗
Endocr Regul. 2011 Oct;45(4):199-204. doi: 10.4149/endo_2011_04_199.

引用本文的文献

1
Osteoporosis in Wilson's disease: A large cohort study highlighting age, sex and skeletal symptoms as key risk factors for clinical surveillance.威尔逊病中的骨质疏松症:一项大型队列研究强调年龄、性别和骨骼症状是临床监测的关键危险因素。
Orphanet J Rare Dis. 2025 Jul 29;20(1):388. doi: 10.1186/s13023-025-03910-1.
2
Primary Osteoporosis Induced by Androgen and Estrogen Deficiency: The Molecular and Cellular Perspective on Pathophysiological Mechanisms and Treatments.雄激素和雌激素缺乏引起的原发性骨质疏松症:病理生理机制和治疗的分子和细胞视角。
Int J Mol Sci. 2024 Nov 12;25(22):12139. doi: 10.3390/ijms252212139.
3
Implementation of fracture risk assessment in men with prostate cancer requiring long-term androgen deprivation therapy: a systematic scoping review using the i-PARIHS implementation framework.

本文引用的文献

1
Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis.雄激素剥夺疗法与前列腺癌患者血栓栓塞事件的关联:系统评价和荟萃分析。
Prostate Cancer Prostatic Dis. 2018 Nov;21(4):451-460. doi: 10.1038/s41391-018-0059-4. Epub 2018 Jul 9.
2
Impact of Early Salvage Androgen Deprivation Therapy in Localized Prostate Cancer after Radical Prostatectomy: A Propensity Score Matched Analysis.早期挽救性雄激素剥夺疗法对前列腺癌根治术后局限性前列腺癌的影响:一项倾向评分匹配分析
Yonsei Med J. 2018 Jul;59(5):580-587. doi: 10.3349/ymj.2018.59.5.580.
3
在需要长期雄激素剥夺治疗的前列腺癌男性中实施骨折风险评估:使用i-PARIHS实施框架的系统综述
J Cancer Surviv. 2024 Aug 14. doi: 10.1007/s11764-024-01659-3.
4
High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.大剂量维生素 D 减轻雄激素剥夺治疗的前列腺癌患者的骨丢失:一项 2 期 RCT 研究。
Cancer. 2024 Jul 15;130(14):2538-2551. doi: 10.1002/cncr.35275. Epub 2024 Mar 23.
5
Frailty of Prostate Cancer Patients Receiving Androgen Deprivation Therapy: A Scoping Review.接受雄激素剥夺治疗的前列腺癌患者的衰弱:一项范围综述。
World J Mens Health. 2024 Apr;42(2):347-362. doi: 10.5534/wjmh.220280. Epub 2023 Nov 7.
6
Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase 3 Randomized Controlled Trial.盆腔外照射对骨密度的影响:一项 3 期随机对照试验的二次分析。
Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):119-126. doi: 10.1016/j.ijrobp.2023.10.046. Epub 2023 Nov 3.
7
Association of Androgen Deprivation Therapy with Osteoporotic Fracture in Patients with Prostate Cancer with Low Tumor Burden Using a Retrospective Population-Based Propensity-Score-Matched Cohort.使用基于人群的回顾性倾向评分匹配队列研究低肿瘤负荷前列腺癌患者雄激素剥夺治疗与骨质疏松性骨折的关联。
Cancers (Basel). 2023 May 18;15(10):2822. doi: 10.3390/cancers15102822.
8
Prostate cancer and bone: clinical presentation and molecular mechanisms.前列腺癌与骨骼:临床表现与分子机制。
Endocr Relat Cancer. 2023 Jul 25;30(9). doi: 10.1530/ERC-22-0360. Print 2023 Sep 1.
9
Cancer Cell-Extrinsic Roles for the Androgen Receptor in Prostate Cancer.雄激素受体在前列腺癌中的肿瘤细胞外作用。
Endocrinology. 2023 Apr 17;164(6). doi: 10.1210/endocr/bqad078.
10
Maintaining bone health by estrogen therapy in patients with advanced prostate cancer: a narrative review.雌激素疗法维持晚期前列腺癌患者的骨骼健康:一项叙述性综述。
Endocr Connect. 2022 Nov 18;11(12). doi: 10.1530/EC-22-0182. Print 2022 Dec 1.
Treatment of Oligometastatic Hormone-Sensitive Prostate Cancer: A Comprehensive Review.
寡转移激素敏感性前列腺癌的治疗:综述
Yonsei Med J. 2018 Jul;59(5):567-579. doi: 10.3349/ymj.2018.59.5.567.
4
Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.关于骨质疏松症药物相对疗效的系统评价和网络荟萃分析:接受持续雄激素剥夺治疗的前列腺癌男性患者降低脆性骨折风险的研究
BJU Int. 2018 Jan;121(1):17-28. doi: 10.1111/bju.14015. Epub 2017 Oct 15.
5
Stroke related to androgen deprivation therapy for prostate cancer: a meta-analysis and systematic review.前列腺癌雄激素剥夺治疗相关的中风:一项荟萃分析与系统评价
BMC Cancer. 2016 Mar 3;16:180. doi: 10.1186/s12885-016-2221-5.
6
Prostate Cancer, Version 1.2016.前列腺癌临床实践指南(2016 年版)
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30. doi: 10.6004/jnccn.2016.0004.
7
Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review.前列腺癌患者的雄激素剥夺治疗与骨质流失:一项临床综述
Bonekey Rep. 2015 Jun 24;4:716. doi: 10.1038/bonekey.2015.85. eCollection 2015.
8
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.系统评价与Meta分析方案的首选报告项目(PRISMA-P)2015声明。
Syst Rev. 2015 Jan 1;4(1):1. doi: 10.1186/2046-4053-4-1.
9
Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.定量评估雄激素剥夺疗法治疗前列腺癌后发生致命和非致命心血管疾病风险的观察性证据:一项荟萃分析。
Eur Urol. 2015 Sep;68(3):386-96. doi: 10.1016/j.eururo.2014.11.039. Epub 2014 Dec 5.
10
Adverse effects of androgen deprivation therapy and strategies to mitigate them.雄激素剥夺治疗的不良反应及其缓解策略。
Eur Urol. 2015 May;67(5):825-36. doi: 10.1016/j.eururo.2014.07.010. Epub 2014 Aug 2.